HDFC Bank to rally 1,500 staff at Tata Mumbai Marathon 2026 to drive cancer awareness

The initiative is being led through the Bank’s CSR programme, Parivartan, in partnership with the Indian Cancer Society

EU clears Eylea 8 mg for retinal vein occlusion, expanding use of long-acting eye therapy

Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike

WuXi Biologics launches PatroLab digital twin platform to transform biologics manufacturing

The launch of PatroLab is a pivotal milestone, marking a paradigm shift in biologics development and manufacturing

Gabby Union-Wade fronts Bayer's new menopause drug, Lynkuet

The collaboration centers on the "Life Doesn't Stop for a Hot Flash" campaign

FDA endorses Relmada’s registrational strategy for bladder cancer therapy

GRIN Therapeutics launches global Phase 3 trial for groundbreaking GRIN-NDD therapy

GRIN-NDD is one of the most complex neurodevelopmental disorders with limited treatment options today

EpiBiologics secures $107 million in Series B to advance tissue-selective cancer therapies

The therapy is mutation-agnostic and aims to overcome limitations of existing EGFR-targeting drugs by concentrating degradation in tumors while sparing healthy tissue

InflaRx shifts focus to lead drug, cuts costs by 30% to extend cash runway

InflaRx is streamlining operations and largely discontinuing non-essential activities outside izicopan’s development

Merck initiates phase 3 trial of calderasib with Keytruda QLEX for NSCLC

KRAS G12C-mutant advanced or metastatic nonsquamous non-small cell lung cancer

Iksuda reports promising early results for HER2-targeted therapy in oesophageal cancer

The Phase 1 study, a non-randomised, open-label, multicentre trial, is evaluating IKS014 in patients with locally advanced or metastatic solid tumours expressing HER2